These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26416303)

  • 1. Can pretreatment serum calcium level predict the efficacy of methotrexate in the treatment of severe plaque psoriasis?
    Zhai Z; Chen L; Yang H; Yan J; Wang C; Yang J; Liu W; Shen Z
    J Am Acad Dermatol; 2015 Dec; 73(6):991-7.e3. PubMed ID: 26416303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
    Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of disease severity with IL-1 levels in methotrexate-treated psoriasis patients.
    Tamilselvi E; Haripriya D; Hemamalini M; Pushpa G; Swapna S
    Scand J Immunol; 2013 Dec; 78(6):545-53. PubMed ID: 24283773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
    Dogra S; Krishna V; Kanwar AJ
    Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum interleukin-6 levels in response to methotrexate treatment in psoriatic patients.
    Elango T; Dayalan H; Subramanian S; Gnanaraj P; Malligarjunan H
    Clin Chim Acta; 2012 Oct; 413(19-20):1652-6. PubMed ID: 22609260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial.
    Radmanesh M; Rafiei B; Moosavi ZB; Sina N
    Int J Dermatol; 2011 Oct; 50(10):1291-3. PubMed ID: 21950300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate treatment provokes apoptosis of proliferating keratinocyte in psoriasis patients.
    Elango T; Thirupathi A; Subramanian S; Ethiraj P; Dayalan H; Gnanaraj P
    Clin Exp Med; 2017 Aug; 17(3):371-381. PubMed ID: 27435483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in children.
    Rahman SI; Siegfried E; Flanagan KH; Armbrecht ES
    J Am Acad Dermatol; 2014 Feb; 70(2):252-6. PubMed ID: 24332314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Subcutaneous Methotrexate in Chronic Plaque Psoriasis.
    Yesudian PD; Leman J; Balasubramaniam P; Macfarlane AW; Al-Niaimi F; Griffiths CE; Burden AD; Warren RB
    J Drugs Dermatol; 2016 Mar; 15(3):345-9. PubMed ID: 26954320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
    Salim A; Tan E; Ilchyshyn A; Berth-Jones J
    Br J Dermatol; 2006 Jun; 154(6):1169-74. PubMed ID: 16704650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions.
    Inzinger M; Weger W; Heschl B; Salmhofer W; Quehenberger F; Wolf P
    J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):861-6. PubMed ID: 22672248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of the effect of narrowband ultraviolet B phototherapy plus methotrexate vs. narrowband ultraviolet B alone and methotrexate alone in the treatment of plaque-type psoriasis.
    Al-Hamamy HR; Al-Mashhadani SA; Mustafa IN
    Int J Dermatol; 2014 Dec; 53(12):1531-5. PubMed ID: 24738793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients.
    van Swelm RP; Laarakkers CM; Kooijmans-Otero M; de Jong EM; Masereeuw R; Russel FG
    Toxicol Lett; 2013 Aug; 221(3):219-24. PubMed ID: 23830989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.
    Reich K; Signorovitch J; Ramakrishnan K; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
    J Am Acad Dermatol; 2010 Dec; 63(6):1011-8. PubMed ID: 20933301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate normalized keratinocyte activation cycle by overturning abnormal keratins as well as deregulated inflammatory mediators in psoriatic patients.
    Elango T; Thirupathi A; Subramanian S; Dayalan H; Gnanaraj P
    Clin Chim Acta; 2015 Dec; 451(Pt B):329-37. PubMed ID: 26499845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.
    Chládek J; Simková M; Vanecková J; Hroch M; Vávrová J; Hůlek P
    J Eur Acad Dermatol Venereol; 2013 Aug; 27(8):1007-14. PubMed ID: 22882190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia.
    Ng LC; Lee YY; Lee CK; Wong SM
    Int J Dermatol; 2013 Jan; 52(1):102-5. PubMed ID: 23278617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.
    Strober BE; Poulin Y; Kerdel FA; Langley RG; Gu Y; Gupta SR; Okun MM; Papp KA
    J Am Acad Dermatol; 2011 Apr; 64(4):671-81. PubMed ID: 21414495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation.
    Avasatthi V; Pawar H; Dora CP; Bansod P; Gill MS; Suresh S
    Pharm Dev Technol; 2016 Aug; 21(5):554-62. PubMed ID: 26024238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.